In this article, we will look at the 10 Best Performing Pharma Stocks in 2025.On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook. He stated that M&A activity started off strong in the year, and that pharma stocks are set to take off in 2026.In addition to the big pharma companies, he believes that biotech, which had a really tough past 3-4 years, is ready to take of ...

Financial Performance - Total revenue increased by 3% year-over-year to $2.53 billion in Q3 2025[59, 61, 64] - Launch products revenue grew 67% year-over-year, reaching $257 million in Q3 2025[19, 59] - GAAP diluted EPS increased by 19% year-over-year to $3.17, while Non-GAAP diluted EPS increased by 18% year-over-year to $4.81[59, 64] - The company generated $1.23 billion of free cash flow in Q3 2025[59] Product Performance - LEQEMBI achieved $121 million in in-market sales, demonstrating sustained sequential global demand growth[19, 48] - SKYCLARYS revenue grew 30% year-over-year and is now available in 34 markets globally[19, 52] - ZURZUVAE revenue increased by over 150% year-over-year, with 80% of prescriptions for first-line therapy[19, 55] Pipeline Advancement - Litifilimab Phase 3 studies for SLE are fully enrolled, with data expected in H2 2026[19, 34, 41] - A Phase 1 study was initiated for BIIB142, an IRAK4 degrader for autoimmune diseases[19, 21, 34, 35] - The company expects 3-4 potential new INDs[34, 35] Financial Guidance - Full year 2025 Non-GAAP diluted EPS is expected to be between $14.50 and $15.00[59] - Full year 2025 total revenue is expected to be approximately flat to increasing 1% at constant currency[59, 74] - The company expects to deliver $1 billion gross savings / $800 million net savings as part of the "Fit for Growth" initiative by the end of 2025[24, 79]

Core Insights - J. L. Bainbridge & Co. sold 119,376 shares of Biogen for approximately $16.1 million during the third quarter, significantly reducing its holdings to just 2,969 shares valued at $415,898 as of September 30 [2][7] Company Overview - Biogen specializes in therapies for complex neurological and neurodegenerative conditions, with a diversified product suite and a robust pipeline [6][10] - As of the latest market close, Biogen's stock price was $143, with a market capitalization of $21 billion, revenue of $10 billion, and net income of $1.5 billion for the trailing twelve months [4] Financial Performance - Biogen's shares have declined by 23% over the past year, despite a strong second-quarter report showing a 7% year-over-year revenue growth to $2.6 billion and raised full-year guidance [3][8] - The company highlighted growth in its Alzheimer's therapy LEQEMBI, rare-disease drug SKYCLARYS, and postpartum-depression treatment ZURZUVAE, indicating strong execution in reshaping its portfolio for sustainable growth [11] Investment Strategy - J. L. Bainbridge's decision to significantly reduce its Biogen holdings aligns with its strategy to concentrate on proven large-cap growth names like Microsoft, Apple, and Alphabet [12] - The upcoming earnings report on October 30 will be crucial for assessing whether Biogen's new drug launches can offset the decline in its older franchises [12]

Financial Performance - Total revenue increased by 7% year-over-year to $265 billion[53] - Launch products generated $252 million in revenue, a 26% increase quarter-over-quarter and a 91% increase year-over-year[53] - Non-GAAP diluted EPS increased by 4% year-over-year to $547[53] - The company generated $134 million of free cash flow, which includes a $745 million impact from Q2 2025 tax payments[53] - The company expects full-year 2025 Non-GAAP diluted EPS between $1550 and $1600, up from the previous guidance of $1450 to $1550[53] - The company expects full-year 2025 total revenue to be approximately flat at constant currency versus FY 2024, an increase from a mid-single-digit decline previously[53] Product Performance - SKYCLARYS worldwide sales reached $130 million in Q2, up 30% year-over-year and 5% quarter-over-quarter[47] - SKYCLARYS U S sales were $78 million, up 3% year-over-year and 13% quarter-over-quarter[47] - ZURZUVAE U S sales were $46 million in Q2, up 213% year-over-year and 68% quarter-over-quarter[48] - LEQEMBI worldwide sales were $160 million in Q2, excluding $35 million in stocking in China; U S sales increased 20% quarter-over-quarter to $63 million[49] Pipeline and Development - Phase 3 studies were initiated for felzartamab in IgAN and PMN, and for SKYCLARYS in pediatric FA[18] - Positive Phase 1b results for salanersen support moving to registrational status for SMA, with a Phase 3 study expected to start by early 2026[18,32] - New analyses of dapirolizumab pegol Phase 3 data in SLE show improvement in fatigue and reduction in disease activity[18]

Core Viewpoint - Analysts forecast a significant decline in Biogen Inc.'s quarterly earnings and revenues, indicating potential challenges for the company in the upcoming earnings release [1][2]. Financial Performance Estimates - Expected earnings per share (EPS) for Biogen is $3.94, reflecting a year-over-year decline of 25.4% [1]. - Anticipated revenues are projected at $2.32 billion, which is a decrease of 5.8% compared to the same quarter last year [1]. Revisions and Trends - Over the past 30 days, the consensus EPS estimate has been revised downward by 2.7%, indicating a shift in analysts' expectations [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Product Revenue Estimates - Revenue from the product TYSABRI for Multiple Sclerosis is estimated at $372.66 million, down 19.4% year-over-year [5]. - Revenue from SPINRAZA for Rare Disease is projected at $396.92 million, indicating a decline of 7.5% year-over-year [5]. - SKYCLARYS for Rare Disease is expected to generate $128.37 million, showing a year-over-year increase of 28.4% [5]. Detailed Product Revenue Breakdown - Total net product revenue is estimated to be $1.72 billion, reflecting a year-over-year decrease of 9.5% [6]. - TYSABRI revenue in the United States is projected at $203.91 million, down 18% year-over-year [6]. - Revenue from TECFIDERA in the United States is expected to be $32.02 million, indicating a decline of 27.4% year-over-year [7]. Additional Revenue Insights - SPINRAZA revenue from the Rest of World is estimated at $244.01 million, down 10.2% from the previous year [8]. - Revenue from SPINRAZA in the United States is projected at $156.29 million, showing a slight decline of 0.6% year-over-year [8]. - Revenue from Interferon products in the United States is expected to be $129.57 million, reflecting a decrease of 10.9% year-over-year [9]. Stock Performance - Over the past month, Biogen's shares have decreased by 1.7%, contrasting with a 3.4% increase in the Zacks S&P 500 composite [10]. - Biogen currently holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [10].